Newsroom

International MIGS Study Confirms Long-Term Safety and Efficacy of the OMNI® Surgical System Predicate Device (VISCO360®)

Sight Sciences, Inc., today announced a new, single center study of glaucoma surgery patients published in the July 2019 issue of Clinical Ophthalmology, which shows that ab-interno microcatheterization and 360˚...

read more +
First International MIGS Data for the OMNI® Surgical System Presented at ESCRS

Sight Sciences announced clinical results from the first study of the OMNI® Surgical System in glaucoma patients were presented at the European Society of Cataract and Refractive Surgery (ESCRS). Findings from...

read more +
Sight Sciences Raises $56M of Growth Capital to Lead the Development of the Standalone MIGS Market and Procedure-Based Dry Eye Market

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced the closing of $31 million...

read more +
Sight Sciences Hires Leading Industry Executives to Drive Continued Growth

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced that Jessica Holmes, Brian Regan...

read more +
First Subject Enrolled in large, multi-center pivotal trial to confirm safety and efficacy of TearCare® in the treatment of signs and symptoms of Dry Eye disease

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye, today announced the first subject has been enrolled...

read more +
Sight Sciences Announces Official Launches of TearCare® and the Enhanced, Next Generation OMNI® System

New Dry Eye and MIGS Entrants will be Prominently Featured in Product Demonstrations and Events at Upcoming Industry Shows MENLO PARK, Calif. – Sight Sciences, Inc., a growth-stage medical device company...

read more +
First Subjects Enrolled in Clinical Study to Evaluate Safety and Efficacy of OMNI™ Surgical System for Multiple Micro-Invasive Glaucoma Surgery Procedures

MENLO PARK, Calif. – Sight Sciences today announced enrollment has begun in the Gemini clinical study, a Sight Sciences-sponsored, prospective, multi-center study to evaluate the safety and efficacy of the OMNI™...

read more +
Clinical Study Demonstrates Long Term IOP Reduction With The OMNI® Surgical System Predicate Device (TRAB®360) In Micro-Invasive Glaucoma Surgery

A new, single center retrospective study of glaucoma surgery patients published in the January 2019 issue of Clinical Ophthalmology shows that ab-interno trabeculotomy using one of Sight Sciences’ OMNI® Surgical System’s...

read more +